These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
550 related items for PubMed ID: 21498633
1. A genome-wide search for promoters that respond to increased MYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma. Shohet JM, Ghosh R, Coarfa C, Ludwig A, Benham AL, Chen Z, Patterson DM, Barbieri E, Mestdagh P, Sikorski DN, Milosavljevic A, Kim ES, Gunaratne PH. Cancer Res; 2011 Jun 01; 71(11):3841-51. PubMed ID: 21498633 [Abstract] [Full Text] [Related]
9. Dissection of the oncogenic MYCN transcriptional network reveals a large set of clinically relevant cell cycle genes as drivers of neuroblastoma tumorigenesis. Murphy DM, Buckley PG, Bryan K, Watters KM, Koster J, van Sluis P, Molenaar J, Versteeg R, Stallings RL. Mol Carcinog; 2011 Jun 01; 50(6):403-11. PubMed ID: 21557326 [Abstract] [Full Text] [Related]
10. Unveiling MYCN regulatory networks in neuroblastoma via integrative analysis of heterogeneous genomics data. Hsu CL, Chang HY, Chang JY, Hsu WM, Huang HC, Juan HF. Oncotarget; 2016 Jun 14; 7(24):36293-36310. PubMed ID: 27167114 [Abstract] [Full Text] [Related]
12. MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas. Huang R, Cheung NK, Vider J, Cheung IY, Gerald WL, Tickoo SK, Holland EC, Blasberg RG. FASEB J; 2011 Dec 14; 25(12):4138-49. PubMed ID: 21856782 [Abstract] [Full Text] [Related]
13. Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma. Schramm A, Köster J, Marschall T, Martin M, Schwermer M, Fielitz K, Büchel G, Barann M, Esser D, Rosenstiel P, Rahmann S, Eggert A, Schulte JH. Int J Cancer; 2013 Feb 01; 132(3):E106-15. PubMed ID: 22907398 [Abstract] [Full Text] [Related]
14. MYCN is recruited to the RASSF1A promoter but is not critical for DNA hypermethylation in neuroblastoma. Charlet J, Szemes M, Malik KT, Brown KW. Mol Carcinog; 2014 May 01; 53(5):413-20. PubMed ID: 23280764 [Abstract] [Full Text] [Related]
15. MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors. Mestdagh P, Fredlund E, Pattyn F, Schulte JH, Muth D, Vermeulen J, Kumps C, Schlierf S, De Preter K, Van Roy N, Noguera R, Laureys G, Schramm A, Eggert A, Westermann F, Speleman F, Vandesompele J. Oncogene; 2010 Mar 04; 29(9):1394-404. PubMed ID: 19946337 [Abstract] [Full Text] [Related]
18. MYCN-regulated microRNAs repress estrogen receptor-alpha (ESR1) expression and neuronal differentiation in human neuroblastoma. Lovén J, Zinin N, Wahlström T, Müller I, Brodin P, Fredlund E, Ribacke U, Pivarcsi A, Påhlman S, Henriksson M. Proc Natl Acad Sci U S A; 2010 Jan 26; 107(4):1553-8. PubMed ID: 20080637 [Abstract] [Full Text] [Related]
19. Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. Chen Y, Stallings RL. Cancer Res; 2007 Feb 01; 67(3):976-83. PubMed ID: 17283129 [Abstract] [Full Text] [Related]